Top

Reviews in Endocrine and Metabolic Disorders

Published in:

26-12-2023 | Hypopituitarism

Cognition and psychological wellbeing in hypopituitary patients

Authors: Syed Ali Imran, Michael Wilkinson

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 3/2024

Abstract

Hypopituitarism (HP) frequently occurs in patients presenting with sellar masses and despite recent advances in therapeutic options, HP patients consistently suffer from impaired quality of life due to psychological distress and cognitive dysfunction. These neurocognitive complications tend to persist in spite of surgical or biochemical remission of the disease making it especially challenging to segregate the effect of HP per se from other comorbidities such as the effect of tumour, surgery, radiation therapy, or complications caused by excess hormone production. Regardless, there is ample evidence to suggest that receptors for various pituitary hormones are abundantly expressed in key areas of central nervous system that are associated with memory and behaviour function and HP is also associated with poor sleep which can further exacerbate neurocognitive dysfunction. There is also evidence that hormonal replacement in HP patients partially restores these neurocognitive functions and improves sleep disorders. However, there is a need for creating better awareness among healthcare providers interacting with HP patients to enhance an earlier recognition of these disorder and their impact on quality of life despite initial remission. Importantly, there is a need to not only develop better and more cost-effective replacement therapies that would closely mimic the physiological hormonal release patterns, but also develop coping strategies for HP patients suffering from these complications.

Al-Dahmani K, Mohammad S, Imran F, et al. Sellar masses: an epidemiological study. Can J Neurol Sci. 2016;43:291–7. https://doi.org/10.1017/cjn.2015.301.CrossRefPubMed

Imran SA, Yip CE, Papneja N, et al. Analysis and natural history of pituitary incidentalomas. Eur J Endocrinol. 2016;175:1–9. https://doi.org/10.1530/EJE-16-0041.CrossRefPubMed

Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173–82. https://doi.org/10.1001/jamaoncol.2017.3064.CrossRefPubMed

Regal M, Páramo C, Sierra SM, et al. Prevalence and incidence of hypopituitarism in an adult caucasian population in northwestern Spain. Clin Endocrinol. 2001;55:735–40. https://doi.org/10.1046/j.1365-2265.2001.01406.x.CrossRef

Jasim S, Alahdab F, Ahmed AT, et al. Mortality in adults with hypopituitarism: a systematic review and meta-analysis. Endocrine. 2017;56:33–42. https://doi.org/10.1007/s12020-016-1159-3.CrossRefPubMed

Ehrnborg C, Hakkaart-Van Roijen L, et al. Cost of Illness in adult patients with hypopituitarism. PharmacoEconomics. 2000;17:621–8. https://doi.org/10.2165/00019053-200017060-00008.CrossRefPubMed

Tiemensma J, Biermasz NR, van der Mast RC, et al. Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly. J Clin Endocrinol Metab. 2010;95:E392–402.CrossRefPubMed

Pivonello R, Auriemma RS, Delli Veneri A, et al. Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study. Eur J Endocrinol. 2022;187:823–45. https://doi.org/10.1530/EJE-22-0263.CrossRefPubMedPubMedCentral

Broersen LHA, Andela CD, Dekkers OM, et al. Improvement but no normalization of quality of life and cognitive functioning after treatment of Cushing Syndrome. J Clin Endocrinol Metab. 2019;104:5325–37. https://doi.org/10.1210/jc.2019-01054.CrossRefPubMed

10.

Tiemensma J, Biermasz NR, Middelkoop HA, et al. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing’s Disease. J Clin Endocrinol Metab. 2010;95:E129–141. https://doi.org/10.1210/jc.2010-0512.CrossRefPubMed

11.

Kars M, van der Klaauw AA, Onstein CS, et al. Quality of life is decreased in female patients treated for microprolactinoma. Eur J Endocrinol. 2007;157:133–9. https://doi.org/10.1530/EJE-07-0259.CrossRefPubMed

12.

Sievers C, Ising M, Pfister H, et al. Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls. Eur J Endocrinol. 2009;160:367–73. https://doi.org/10.1530/EJE-08-0896.CrossRefPubMed

13.

Zada G, Kintz N, Pulido M, et al. Prevalence of neurobehavioral, social, and emotional dysfunction in patients treated for childhood craniopharyngioma: a systematic literature review. PLoS ONE. 2013;8:e76562. https://doi.org/10.1371/journal.pone.0076562.CrossRefPubMedPubMedCentral

14.

Imran SA, Tiemensma J, Kaiser SM, et al. Morphometric changes correlate with poor psychological outcomes in patients with acromegaly. Eur J Endocrinol. 2016;174:41–50. https://doi.org/10.1530/EJE-15-0888.CrossRefPubMed

15.

Chen J, Xiang Z, Zhang Z, et al. Cognitive dysfunction, an increasingly valued long-term impairment in acromegaly. J Clin Med. 2023;12:2283. https://doi.org/10.3390/jcm12062283.CrossRefPubMedPubMedCentral

16.

Bengtsson D, Ragnarsson O, Berinder K, et al. Psychotropic Drugs in patients with Cushing’s Disease before diagnosis and at long-term follow-up: a nationwide study. J Clin Endocrinol Metab. 2021;106:1750–60. https://doi.org/10.1210/clinem/dgab079.CrossRefPubMedPubMedCentral

17.

van der Meulen M, Zamanipoor Najafabadi AH, Lobatto DJ, et al. Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants. Pituitary. 2021;24:79–95. https://doi.org/10.1007/s11102-020-01089-1.CrossRefPubMed

18.

Bala A, Dziedzic T, Olejnik A, et al. Attention and working memory in patients with prolactinomas: a case-control study. Sci Rep. 2022;12:22565. https://doi.org/10.1038/s41598-022-26331-7.CrossRefPubMedPubMedCentral

19.

Yedinak CG, Fleseriu M. Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study. Endocrine. 2014;46:585–93. https://doi.org/10.1007/s12020-013-0106-9.CrossRefPubMed

20.

Brummelman P, Elderson MF, Dullaart RP, et al. Cognitive functioning in patients treated for nonfunctioning pituitary macroadenoma and the effects of pituitary radiotherapy. Clin Endocrinol. 2011;74:481–7. https://doi.org/10.1111/j.1365-2265.2010.03947.x.CrossRef

21.

Fournier-Goodnight AS, Ashford JM, Merchant TE, et al. Neurocognitive functioning in pediatric craniopharyngioma: performance before treatment with proton therapy. J Neurooncol. 2017;134:97–105. https://doi.org/10.1007/s11060-017-2492-y.CrossRefPubMedPubMedCentral

22.

Aldave G, Okcu MF, Chintagumpala M, et al. Comparison of neurocognitive and quality-of-life outcomes in pediatric craniopharyngioma patients treated with partial resection and radiotherapy versus gross-total resection only. J Neurosurg Pediatr. 2023;31:453–62. https://doi.org/10.3171/2022.12.PEDS22367.CrossRefPubMed

23.

Slagboom TNA, Deijen JB, Van Bunderen CC, et al. Psychological well-being and Illness perceptions in patients with hypopituitarism. Pituitary. 2021;24:542–54. https://doi.org/10.1007/s11102-021-01131-w.CrossRefPubMedPubMedCentral

24.

Mahajan C, Prabhakar H, Bilotta F. Endocrine dysfunction after traumatic Brain Injury: an ignored clinical syndrome? Neurocrit Care. 2023. https://doi.org/10.1007/s12028-022-01672-3.CrossRefPubMedPubMedCentral

25.

Wass JA, Reddy R. Growth hormone and memory. J Endocrinol. 2010;207:125–6. https://doi.org/10.1677/JOE-10-0126.CrossRefPubMed

26.

Moreau OK, Cortet-Rudelli C, Yollin E. Growth hormone replacement therapy in patients with traumatic brain injury. J Neurotrauma. 2013;30:998–1006. https://doi.org/10.1089/neu.2012.2705.CrossRefPubMed

27.

Arwert LI, Deijen JB, Müller M, et al. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm Behav. 2005;47:343–9. https://doi.org/10.1016/j.yhbeh.2004.11.015.CrossRefPubMed

28.

Blackmore DG, Waters MJ. The multiple roles of GH in neural ageing and injury. Front Neurosci. 2023;17:1082449. https://doi.org/10.3389/fnins.2023.1082449.CrossRefPubMedPubMedCentral

29.

Nyberg F, Burman P. Growth hormone and its receptors in the central nervous system - location and functional significance. Horm Res. 1996;45:18–22. https://doi.org/10.1159/000184753.CrossRefPubMed

30.

Castro JR, Costoya JA, Gallego R, et al. Expression of growth hormone receptor in the human brain. Neurosci Letts. 2000;281:147–50. https://doi.org/10.1016/s0304-3940(00)00830-2.CrossRef

31.

Mercado M, Dávila N, McLeod JF, et al. Distribution of growth hormone receptor messenger ribonucleic acid containing and lacking exon 3 in human tissues. J Clin Endocrinol Metab. 1994;78:731–5. https://doi.org/10.1210/jcem.78.3.8126150.CrossRefPubMed

32.

Lai Z, Emtner M, Roos P, et al. Characterization of putative growth hormone receptors in human choroid plexus. Brain Res. 1991;546:222–6. https://doi.org/10.1016/0006-8993(91)91485-j.CrossRefPubMed

33.

Lai Z, Roos P, Zhai Q, et al. Age-related reduction of human growth hormone binding sites in the human brain. Brain Res. 1993;621:260–6. https://doi.org/10.1016/0006-8993(93)90114-3.CrossRefPubMed

34.

Johansson JO, Larson G, Andersson M, et al. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinol. 1995;61:57–66. https://doi.org/10.1159/000126813.CrossRef

35.

Burman P, Hetta J, Wide L, et al. Growth hormone treatment affects brain neurotransmitters and thyroxine. Clin Endocrinol. 1996;44:319–24. https://doi.org/10.1046/j.1365-2265.1996.617439.x.CrossRef

36.

Linfoot JA, Garcia JF, Wei W, et al. Human growth hormone levels in cerebrospinal fluid. J Clin Endocrinol. 1970;31:230–2. https://doi.org/10.1210/jcem-31-2-230.CrossRef

37.

Coculescu M, Simionescu L, Constantinovici A, et al. High level of human growth hormone (HGH) in cerebrospinal fluid patients with pituitary tumors. Endocrinologie. 1979;17:205–11.PubMed

38.

Coculescu M. Blood-brain barrier for human growth hormone and insulin-like growth factor-1. J Ped Endocrinol Metab. 1999;12:113–24. https://doi.org/10.1515/jpem.1999.12.2.113.CrossRef

39.

Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin-like growth factor receptor. Metabolism. 1988;37:136–40. https://doi.org/10.1016/s0026-0495(98)90007-5.CrossRefPubMed

40.

Burman P, Hetta J, Karlsson A. Effects of growth hormone on brain neurotransmitters. Lancet. 1993;342:1492–3. https://doi.org/10.1016/0140-6736(93)92975-y.CrossRefPubMed

41.

Aström C, Lindholm J. Growth hormone-deficient young adults have decreased deep sleep. Neuroendocrinol. 1990;51:82–4. https://doi.org/10.1159/000125320.CrossRef

42.

Aström C, Pedersen SA, Lindholm J. The influence of growth hormone on sleep in adults with growth hormone deficiency. Clin Endocrinol. 1990;33:495–500. https://doi.org/10.1111/j.1365-2265.1990.tb03886.x.CrossRef

43.

Garcia JM, Merriam GR, Kargi AY. Growth hormone in aging. https://endotext.org/wp-content/uploads/pdfs/growth-hormone-in-aging.pdf.

44.

Vitiello MV, Schwartz RS, Moe KE, et al. Treating age-related changes in somatotrophic hormones, sleep, and cognition. Dialogues Clin Neurosci. 2001;3:229–36. https://doi.org/10.31887/DCNS.2001.3.3/mvvitiello.CrossRefPubMedPubMedCentral

45.

Slawik M, Klawitter B, Meiser E, et al. Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab. 2007;92:4115–22. https://doi.org/10.1210/jc.2007-0297.CrossRefPubMed

46.

Naicker M, Naidoo S. Cellular and molecular distribution of thyroid-specific proteins, thyroid-stimulating hormone receptor (TSH-R) and thyroglobulin (TG) in the central nervous system. Neurochem Int. 2022;155:10535. https://doi.org/10.1016/j.neuint.2022.105305.CrossRef

47.

Moodley K, Botha J, Raidoo DM, et al. Immuno-localization of anti-thyroid antibodies in adult human cerebral cortex. J Neurol Sci. 2011;302:114–7.CrossRefPubMed

48.

Spiegel DR, Nelson AB, Lieb DC, et al. A case of psychosis in a patient with secondary adrenal insufficiency: a possible etiological role of a hypocortisolemic-induced increase in proinflammatory cytokines. Innov Clin Neurosci. 2017;1(4):4–10.

49.

Jessani N, Jehangir W, Behman D, et al. Secondary adrenal insufficiency: an overlooked cause of hyponatremia. J Clin Med Res. 2015;7:286–8. https://doi.org/10.14740/jocmr2041w.CrossRefPubMedPubMedCentral

50.

Markov DD, Dolotov OV, Grivennikov IA. The Melanocortin System: a promising target for the development of new antidepressant Drugs. Int J Mol Sci. 2023;24:6664. https://doi.org/10.3390/ijms24076664.CrossRefPubMedPubMedCentral

51.

Berruien NNA, Smith CL. Emerging roles of melanocortin receptor accessory proteins (MRAP and MRAP2) in physiology and pathophysiology. Gene. 2020;757:144949. https://doi.org/10.1016/j.gene.CrossRefPubMedPubMedCentral

52.

Yao S, Song J, Gao J, et al. Cognitive function and serum hormone levels are associated with gray matter decline in female patients with prolactinomas. Front Neurol. 2018;8:742. https://doi.org/10.3389/fneur.2017.00742.CrossRefPubMedPubMedCentral

53.

Song J, Cao C, Wang Y, et al. Response activation and inhibition in patients with prolactinomas: an electrophysiological study. Front Hum Neurosci. 2020;14:170. https://doi.org/10.3389/fneur.2021.638851.CrossRefPubMedPubMedCentral

54.

Rajkumar RP. Prolactin and psychopathology in schizophrenia: A literature review and reappraisal. Schizophrenia Res Treat. 2014; 2014: 175360. https://doi.org/10.1155/2014/175360.

55.

Rastrelli G, Corona G, Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord. 2015;16:233–48. https://doi.org/10.1007/s11154-015-9322-3.CrossRefPubMed

56.

Lašaitė L, Ceponis J, Preikša RT, et al. Impaired emotional state, quality of life and cognitive functions in young hypogonadal men. Andrologia. 2014;46:1107–12. https://doi.org/10.1111/and.12199.CrossRefPubMed

57.

Kałużna M, Kompf P, Rabijewski M, et al. Reduced quality of life and sexual satisfaction in isolated hypogonadotropic hypogonadism. J Clin Med. 2021;10:2622. https://doi.org/10.3390/jcm10122622.CrossRefPubMedPubMedCentral

58.

Federici S, Goggi G, Quinton R, et al. New and consolidated therapeutic options for pubertal induction in hypogonadism: In-depth review of the literature. Endocr Rev. 2022;43:824–51. https://doi.org/10.1210/endrev/bnab043.CrossRefPubMed

59.

Blair JA, Bhatta S, McGee H, et al. Luteinizing hormone: evidence for direct action in the CNS. Horm Behav. 2015;76:57–62. https://doi.org/10.1016/j.yhbeh.2015.06.020.CrossRefPubMedPubMedCentral

60.

Bi WK, Luan SS, Wang J, et al. FSH signaling is involved in affective disorders. Biochem Biophys Res Commun. 2020;525:915–20. https://doi.org/10.1016/j.bbrc.2020.03.039.CrossRefPubMed

61.

Agha A, Thornton E, O’Kelly P. Posterior pituitary dysfunction after traumatic brain injury. J Clin Endocrinol Metab. 2004;89:5987–92. https://doi.org/10.1210/jc.2004-1058.CrossRefPubMed

62.

Coccaro EF, Kavoussi RJ, Hauger RL, et al. Cerebrospinal fluid vasopressin levels. Arch Gen Psychiatry. 1998;55:708–14. https://doi.org/10.1001/archpsyc.55.8.708.CrossRefPubMed

63.

Rae M, Lemos Duarte M, Gomes I. Oxytocin and vasopressin: signalling, behavioural modulation and potential therapeutic effects. Br J Pharmacol. 2022;179:1544–64. https://doi.org/10.1111/bph.15481.CrossRefPubMed

64.

Brownstein MJ, Simon NG, Long JD, et al. Safety and tolerability of SRX246, a vasopressin 1a antagonist, in irritable Huntington’s Disease patients-a randomized phase 2 clinical trial. J Clin Med. 2020;9:3682. https://doi.org/10.3390/jcm9113682.CrossRefPubMedPubMedCentral

65.

Lee RJ, Coccaro EF, Cremers H, et al. A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study. Front Syst Neurosci. 2013;12:7: 100. https://doi.org/10.3389/fnsys.2013.00100.CrossRef

66.

Atila C, Loughrey PB, Garrahy A, et al. Central Diabetes insipidus from a patient’s perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey. Lancet Diabetes Endocrinol. 2022;10:700–9. https://doi.org/10.1016/S2213-8587(22)00219-4.CrossRefPubMed

67.

Atila C, Holze F, Murugesu R, Rommers N, et al. Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central Diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. Lancet Diab Endocrinol. 2023;11:454–64. https://doi.org/10.1016/S2213-8587(23)00120-1.CrossRef

68.

Verbalis JG. Oxytocin deficiency – a ‘new’ human disorder? Nat Revs Endocrinol. 2023;19:505–6. https://doi.org/10.1016/S2213-8587(23)00120-1.CrossRef

69.

Lee R, Ferris C, Van de Kar LD, Coccaro EF. Cerebrospinal fluid oxytocin, life history of aggression, and personality disorder. Psychoneuroendocrinol. 2009;34:1567–73. https://doi.org/10.1016/j.psyneuen.2009.06.002.CrossRef

70.

Jokinen J, Chatzittofis A, Hellström C, et al. Low CSF oxytocin reflects high intent in Suicide attempters. Psychoneuroendocrinol. 2012;37:482–90. https://doi.org/10.1016/j.psyneuen.2011.07.016.CrossRef

71.

Grace SA, Rossell SL, Heinrichs M, et al. Oxytocin and brain activity in humans: a systematic review and coordinate-based meta-analysis of functional MRI studies. Psychoneuroendocrinol. 2018;96:6–24. https://doi.org/10.1016/j.psyneuen.2018.05.031.CrossRef

72.

Wigton R, Radua J, Allen P, et al. Neurophysiological effects of acute oxytocin administration: systematic review and meta-analysis of placebo-controlled imaging studies. J Psychiatry Neurosci. 2015;40:E1–E22. https://doi.org/10.1503/jpn.130289.CrossRefPubMedPubMedCentral

73.

Olsson DS, Svensson M, Labori F, et al. Healthcare cost and survival in patients with non-functioning pituitary adenoma. Eur J Endocrinol. 2023;188:477–84. https://doi.org/10.1093/ejendo/lvad057.CrossRefPubMed

74.

Bancos I, Hahner S, Tomlinson J, et al. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015;3:216–26. https://doi.org/10.1016/S2213-8587(14)70142-1.CrossRefPubMed

75.

Mazziotti G, Mormando M, Cristiano A, et al. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol. 2014;170:893–9. https://doi.org/10.1530/EJE-14-0097.CrossRefPubMed

76.

Martel-Duguech LM, Jorgensen JOL, Korbonits M et al. ESE audit on management of Adult Growth Hormone Deficiency in clinical practice. Eur J Endocrinol. 2020: EJE-20-1180.R1. https://doi.org/10.1530/EJE-20-1180.

77.

Turner J, Kelly B. Emotional dimensions of chronic Disease. West J Med. 2000;172:124–8. https://doi.org/10.1136/ewjm.172.2.124.CrossRefPubMedPubMedCentral

78.

van der Lely AJ, Gomez R, Pleil A, et al. Development of ACRODAT((R)), a new software medical device to assess Disease activity in patients with acromegaly. Pituitary. 2017;20:692–701. https://doi.org/10.1007/s11102-017-0835.CrossRefPubMedPubMedCentral

Title: Cognition and psychological wellbeing in hypopituitary patients
Authors: Syed Ali Imran
Michael Wilkinson
Publication date: 26-12-2023
Publisher: Springer US
Keywords: Hypopituitarism
Prolactinoma
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 3/2024
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-023-09869-3

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

ERS Congress 2024

Springer Medicine

Cognition and psychological wellbeing in hypopituitary patients

Abstract

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

ERS Congress 2024

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2024

Approaching bone health in patients with hypopituitarism

Special features on insulin resistance, metabolic syndrome and vascular complications in hypopituitary patients

New insights into the diagnosis and treatment of arginine vasopressin deficiency

Androgen deficiency in hypopituitary women: its consequences and management

Progress, challenges and perspectives in the management of hypopituitarism

The clinical approach to fertility in women with hypopituitarism

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials